InventVacc Biologicals Inc.
InventVacc is a high-quality, cost-effective, and sustainable global vaccine producer dedicated to developing and manufacturing vaccines for rare and infectious diseases. Founded in 2016, the company leverages advanced technology platforms such as conjugation and mRNA to create innovative vaccines. Its mission is to empower healthy living by providing efficacious and affordable vaccines, with a focus on addressing health inequalities worldwide. InventVacc collaborates with government agencies, research institutions, and global partners to bring life-saving vaccines to market, including vaccines for Hia, meningitis, HPV, and other infectious and rare diseases. The company is committed to supporting low-income countries and indigenous populations, with manufacturing facilities in Canada and a pipeline of vaccines in various development stages.
Industries
Nr. of Employees
small (1-50)
InventVacc Biologicals Inc.
Vancouver, British Columbia, Canada, North America
Products
Haemophilus influenzae type a (Hia) vaccine (IVIV 378)
Conjugate vaccine candidate targeting Haemophilus influenzae type a; reported as in Phase 1 in the pipeline.
Meningitis ACYW135 conjugate vaccine (IVIV 304)
Conjugate vaccine candidate against meningococcal serogroups A, C, Y, W135; described as in pre-clinical development.
Pentavalent vaccine (DTaP-IPV-Hib) (IVIV 521)
Conjugate-platform pentavalent vaccine candidate protecting against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and polio; described at discovery stage.
Hexavalent vaccine (DTaP-IPV-Hib-HepB) (IVIV 859)
Conjugate-platform hexavalent vaccine candidate protecting against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio and hepatitis B; described at discovery stage.
HPV high-valency conjugate vaccine (IVIV 820)
High-valency HPV vaccine candidate using a conjugation platform; described at discovery stage.
mRNA airborne infectious disease vaccine (IVIV 391)
mRNA-platform vaccine candidate targeting airborne infectious disease; described at discovery stage.
Haemophilus influenzae type a (Hia) vaccine (IVIV 378)
Conjugate vaccine candidate targeting Haemophilus influenzae type a; reported as in Phase 1 in the pipeline.
Meningitis ACYW135 conjugate vaccine (IVIV 304)
Conjugate vaccine candidate against meningococcal serogroups A, C, Y, W135; described as in pre-clinical development.
Pentavalent vaccine (DTaP-IPV-Hib) (IVIV 521)
Conjugate-platform pentavalent vaccine candidate protecting against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and polio; described at discovery stage.
Hexavalent vaccine (DTaP-IPV-Hib-HepB) (IVIV 859)
Conjugate-platform hexavalent vaccine candidate protecting against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio and hepatitis B; described at discovery stage.
HPV high-valency conjugate vaccine (IVIV 820)
High-valency HPV vaccine candidate using a conjugation platform; described at discovery stage.
mRNA airborne infectious disease vaccine (IVIV 391)
mRNA-platform vaccine candidate targeting airborne infectious disease; described at discovery stage.
Services
Commercial Market Access
Support for commercialization and localization of biologics across regions through partnerships and local manufacturing exploration.
Process Development
Process and analytical development to optimize protein processes, improve product quality and align with phase-appropriate regulatory guidelines.
Automation Design
Automation architecture and integration for continuous manufacturing with emphasis on automated data collection and observability, aligned with ISA-95, ISA-88 and Pharma 4.0 principles.
Clinical & Commercial Manufacturing
Manufacturing services spanning clinical through commercial supply, including cell bank production, manufacturing lot production, logistics monitoring, and traceability controls (chain of identity/custody).
Commercial Market Access
Support for commercialization and localization of biologics across regions through partnerships and local manufacturing exploration.
Process Development
Process and analytical development to optimize protein processes, improve product quality and align with phase-appropriate regulatory guidelines.
Automation Design
Automation architecture and integration for continuous manufacturing with emphasis on automated data collection and observability, aligned with ISA-95, ISA-88 and Pharma 4.0 principles.
Clinical & Commercial Manufacturing
Manufacturing services spanning clinical through commercial supply, including cell bank production, manufacturing lot production, logistics monitoring, and traceability controls (chain of identity/custody).
Expertise Areas
- Vaccine development (conjugate and mRNA)
- Conjugate vaccine technology and chemistry
- mRNA vaccine design and LNP delivery
- Process development and scale-up for biologics
Key Technologies
- Conjugation chemistry (conjugate vaccines)
- mRNA vaccine platforms
- Lipid nanoparticle (LNP) delivery
- Capsular polysaccharide processing